Here’s what you should know:
1. Boston Scientific first invested in Venti in 2016, purchasing a 25 percent stake. The company will pay an additional $160 million to take full ownership.
2. Veniti developed and commercialized the Vici Venous Stent system, which treats venous obstructive diseases in the peripheral venous system.
3. Veniti is attempting to earn FDA approval for the Vici stent system. Veniti submitted a premarket approval application to the FDA in June. If approved, Veniti will be the first stent system specifically designed for the peripheral venous system.
4. Boston Scientific Senior Vice President Jeff Mirviss said, “We believe the Vici stent will become an important choice for physicians who choose stents to treat patients suffering from venous disease.”
More articles on supply chain:
Dr. William Karnes: Key trends and challenges in GI today.
‘On demand’ extends to healthcare: Consumers want one-stop shopping
Male internists earn on average $50K more than females: 4 study facts
